Introduction
In western countries Trypanosoma cruzi infection with secondary Chagas cardiomyopathy is unusual. The most frequent aetiologies of cardiac arrhythmias are related to atherosclerosis, valvular cardiac pathologies and genetic mutations. In 2013, a patient with Chagas cardiomyopathy was described in the USA [1] . We report a patient with a similar pathology.
Patient
A 58-year-old man was born and lived in rural areas of Central America until, at the age of 23, he immigrated to Switzerland. His parents (mother at the age of 50, father at the age of 54 years) died because of a cardiac pa- 
Findings:
The general status was moderately reduced, the weight was normal. The blood pressure was 138/ 78 mm Hg. The lungs were clear. Palpation of the epigastrium elicited mild pain. The first and second heart sounds had normal tone but there was a nonrespiratory sinus arrhythmia with many premature beats; first to second degree systolic murmurs were heard over all valves. Haematological and chemistry laboratory tests showed that troponin T and D-dimer values were normal but N-terminal of the prohormone brain natriuretic peptide (NT-proBNP) was highly increased (3 387 pg/ml). ECG ( fig. 3) showed sinus tachycardia (100 bpm), frequent supraventricular premature beats
Summary
In western countries patients with a Trypanosoma cruzi infection and with Chagas cardiomyopathy are rare. We report the case of a patient with Chagas cardiomyopathy in Switzerland. Therapy: An implantable cardioverter defibrillator device was implanted and the patient was dismissed under medical treatment with amiodarone, perindopril, rivaroxaban, pantoprazole and benznidazole. In the follow-up, amiodarone was substituted with metoprolol retard and perindopril with candesartan. Congestive heart failure increased. The patient was treated with torasemide, low-dose spironolactone, metoprolol retard, valsartan/ sacubitril, rivaroxaban and pantoprazole and signs and symptoms of heart failure were controlled.
Conclusion:
The chronic parasitic T. cruzi infection may be asymptomatic.
However, after decades a highly arrhythmogenic cardiomyopathy occurs in up to 30% of patients. Gastrointestinal Chagas disease is less frequent. 
Six-month follow-up
In 
Sixteen-month follow-up
The patient complained of recurring moderate dyspnoea and pitting leg oedema. NT-proBNP was in- and it was hypothesised that it would positively affect the cardiomyopathy [2] . Unfortunately, a recent paper confirmed that benznidazole significantly reduces se- Pa tients are categorised as low (0 to 6 points), intermediate (7 to 11 points) and high risk (12 to 20 points). The 10-year mortality rates were 10%, 44% and 84%, respectively. Our patient had 18 points and was at high risk.
Unfortunately, benznidazole was found to be unable to stop the progression of the cardiomyopathy in chronic
Chagas disease. The long-term prognosis of Chagas cardiomyopathy remains poor. American immigrants with nonischaemic heart disease) [2] . Because Chagas disease is rare in Europe, women at risk for congenital transmission to their infants are rarely screened and in patients cardiac and gastro intestinal pathologies are often diagnosed at a late stage [2] .
Infected European patients

Diagnosis of Chagas disease
The first step for diagnosing Chagas disease is the his- Most infected persons are asymptomatic but are permanently infected [2] [3] [4] [5] [6] [8] [9] [10] . Over decades up to 30% of infected patients develop Chagas cardiomyopathy, which is highly arrhythmogenic [1] [2] [3] [4] [5] [6] [8] [9] [10] . Orally transmitted T. cruzi infection appears to be associated with a higher incidence of myocarditis and death than vectorborne infection [11] .
Complications
Chagas cardiomyopathy is highly arrhythmogenic. cific for Chagas cardiomyopathy but indicate that the heart is affected years before the pathology becomes symptomatic.
Gastrointestinal Chagas disease predominantly affects the oesophagus, colon, or both and results from damage to intramural neurons [2, 8] . It is less frequent than Chagas cardiomyopathy and is more common in Argentina, Bolivia, Chile, Paraguay, Uruguay, and parts of Brazil than in northern South and Central America [2, [8] [9] [10] [11] . It was suggested that this geographic pattern might derive from different genotypes of T. cruzi [2, [11] [12] [13] but, in several studies, no strain differences have been detected between infections with and without gastrointestinal manifestations [8, 13, 14] . 
Pathogenesis
Therapy
Progress has been made in the past 5 years toward improving the treatment of Chagas disease [2] . Rarely
Chagas infection may be recognized in the early phase and the trypanocidal drug benznidazole can be used to reduce the level of parasitaemia of T. cruzi and might be useful to treat acute infections [2] . However, a recent study has demonstrated that therapy with benznidazole has no detectable effects in patients with established Chagas cardiomyopathy [3] . T. cruzi infection remains the most important parasitic disease in South,
Central and North America, with an estimated disease burden (measured by disability-adjusted life-years) that is 7.5 times as great as that of malaria [18] . These facts show the need of an urgent search for a treatment with high efficacy during the chronic phase.
There is no specific cardiac therapy for Chagas cardiomyopathy. The disease is highly arrhythmogenic.
Therefore, bradycardic arrhythmias, AV-and/or bundle-branch blocks and complex ectopic arrhythmias are a proven indication for a pacemaker and/or ICD implan tation. Atrial flutter and/or fibrillation are frequent complications and high-risk patients (assessed with the CHA2-DS2-VASc score) need oral anticoagulation. Congestive heart failure is empirically treated as recommended in modern guidelines [19] . As yet there are no trials on the use of valsartan/sacubitril in Chagas cardiomyopathy, but our personal opinion is to use this therapy when Chagas patients develop clear signs of heart failure.
The therapy of gastrointestinal Chagas is also empirical and is adapted to symptoms and signs of the pathology [7] .
